PCSK9抑制剂的研究进展

李 璐, 阳 军
湖南省长沙市中医医院（长沙市第八人民医院） 湖南省长沙市 410000

摘要

摘要：高低密度脂蛋白胆固醇（LDL-C）是动脉粥样硬化性心血管疾病（ASCVD）的最重要的危险因素之一。证据表明（LDL-C）水平高低与ASCVD风险呈正相关，降低（LDL-C）是ASCVD一级和二级预防的关键策略之一。目前，他汀类药物通过降低（LDL-C）水平能够显著降低心血管风险，然而临床上仍有心血管剩余风险、以及他汀不耐受以及（LDL-C）水平不达标等问题。前蛋白转化酶枯草杆菌蛋白酶kexin9型（proproteinconvertasesubtilisin/keintype9，PCSK9）抑制剂能够大幅度降低（LDL-C）水平，是目前降脂及ASCVD防治的新药。本文就PCSK9基因与家族性高胆固醇血症（FH）及动脉粥样硬化，感染的关系，PCSK9抑制剂的研究现状及最新临床进展等方面进行综述。

关键词

关键词：动脉粥样硬化；心血管风险；低密度脂蛋白胆固醇；PCSK9抑制剂；家族性高胆固醇血症

参考

[1] Seidah NG, Benjannet S, Wickham L,et al. The secretory proprotein convertaseneural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuro-nal differentiation.[J].Proc Natl Acad Sci U S A.2003,2,100(3):928-933.[2] Weir HK, Anderson RN, Coleman King SM,et al. Heart Disease and Cancer41Deaths-Trends and Projections in the United States, 1969-2020.[J].Prev ChronicDis.2016,11,13:E157[3] Budha NR, Leabman M,et al. Modeling and Simulation to Support Phase 2 DoseSelection for RG7652, a Fully Human Monoclonal Antibody Against ProproteinConvertase Subtilisin/Kexin Type 9.[J].AAPS.2015,6,17(4):881-890[4] Bonaca MP, Nault P,et al. Low-Density Lipoprotein Cholesterol Lowering WithEvolocumab and Outcomes in Patients With Peripheral Artery Disease: InsightsFrom the FOURIER Trial(Further Cardiovascular Outcomes Research WithPCSK9 Inhibition in Subjects With Elevated Risk). [J]. Circulation. 2018,01,137(4):338-350.[5] Gaudet D,Watts GF,et al. Effect of Alirocumab on Lipoprotein(a) Over≥1.5 Years （from the Phase 3 ODYSSEY Program）.[J]. J Am Cardiol. 2017,01, 119(1):40-46.[6] Khan AR, Bavishi C,et al. Increased Risk of Adverse Neurocognitive OutcomesWith Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors.[J]. Circ Cardiova-sc Qual Outcomes.2017,01,10(1).